Cancer Chemotherapy and Pharmacology

, Volume 6, Issue 2, pp 121–125 | Cite as

Effect of concurrent calcium leucovorin infusion on 5-fluorouracil cytotoxicity against murine L1210 leukemia

  • Philip Klubes
  • Ingeborg Cerna
  • Maura A. Meldon
Original Articles 5-FU+Leucovorin L-1210
Received:
Accepted:

Summary

We examined the effect of concurrent SC infusion of calcium leucovorin (LV) on the action of 5-fluorouracil (FUra) against mouse L1210 leukemia implanted either SC or IP. Mice bearing the SC tumor treated with FUra (100 mg/kg, IP, day 1) plus infusion with either LV (11.5 mg · kg-1 · day-1, days 1–4), or 0.9% NaCl (days 1–4) resulted in an identical increase in median lifespan (ILS) of 28%. Similar experiments with FUra (100 mg/kg) plus LV infusion (115 mg · kg-1 · day-1) or FUra (200 mg/kg) plus LV infusion (115 mg · kg-1 · day-1) resulted in 50% and 59% ILS, respectively, which were not different from that obtained with the same doses of FUra plus 0.9% NaCl infusion. Mice bearing the IP tumor treated with FUra (100 mg/kg, IP, day 1) plus infusion with either LV (11.5 mg · kg-1 · day-1, days 1–4) or 0.9% NaCl (days 1–4) had an identical 56% ILS. Similar experiments with FUra (100 mg/kg) plus LV infusion (115 mg · kg-1 · day-1) or FUra (200 mg/kg) plus LV infusion (115 mg · kg-1 · day-1) resulted in 67% and 94% ILS, respectively, which were not different from those obtained with the same doses of FUra plus 0.9% NaCl infusion. Treatment of normal mice with FUra (200 mg/kg, IP, day 0) plus LV infusion (115 mg · kg-1 · day-1, days 0–3) was no more toxic than FUra plus 0.9% NaCl infusion, judging by similar transient decreases in body weight and no mortality. The data indicate that concurrent infusion with the LV failed to enhance the action of FUra against the mouse L1210 leukemia.

Keywords

Body Weight Leukemia Normal Mouse Leucovorin Transient Decrease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ardalan B, Buscaglia MD, Schein P (1978) Tumor 5-fluorodeoxyuridylate concentrations as a determinant of 5-fluorouracil response. Biochem Pharmacol 27:2009Google Scholar
  2. 2.
    Borsa J, Whitmore GF, Valeriote FA, Collins D, Bruce WR (1969) Studies on the persistence of methotrexate, cytosine arabinoside and leucovorin in serum of mice. J Natl Cancer Inst 42:235Google Scholar
  3. 3.
    Chadwick M, Rogers WI (1972) The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Cancer Res 32:1045Google Scholar
  4. 4.
    Dannenberg PV, Dannenberg KD (1978) Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism. Biochemistry 17:4018PubMedGoogle Scholar
  5. 5.
    Evans RM, Hakala MT (1979) Effect of 5-fluorouracil (FU) alone and in combination with normal metabolites on thymidylate synthetase (TS) and growth in cell culture. Proc Am Assoc Cancer Res 20:154Google Scholar
  6. 6.
    Evans RM, Hakala MT (1980) Role of recovery of thymidylate synthetase (TS) in site of action of 5-fluorouracil (FU) and its modulation with normal metabolites. Proc Am Assoc Cancer Res 21:19Google Scholar
  7. 7.
    Fernandes DF, Klubes P (1979) A biochemical and pharmacological study of therapeutic synergism with 5-fluorouracil plus cyclophosphamide in murine L1210 leukemia. Cancer Res 39:1396Google Scholar
  8. 8.
    Geran RI, Greenberg NG, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems (3rd edn). Cancer Chemother Rep 3 (2, part 3): 1Google Scholar
  9. 9.
    Gibaldi M, Perrier D (1975) Multicompartment models. In: Swarbrick J (ed) Pharmacolinetics. Drugs and the pharmaceutical sciences, vol 1. Marcel Dekker, New York, p 45Google Scholar
  10. 10.
    Goldin A (1978) In vivo metabolite-antimetabolite relationships in antitumor therapy. Adv Enzyme Regul 16:65Google Scholar
  11. 11.
    Grindey GB, Semon JH, Pavelic ZP (1978) Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion. Antibiot Chemother 23:295Google Scholar
  12. 12.
    Heidelberger C (1974) Fluorinated pyrimidines and their nucleosides. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Handbook of Experimental Pharmacology, vol 38, part 1. Springer, New York, p 193Google Scholar
  13. 13.
    Houghton JA, Maroda SJ, Phillips JO, Houghton PJ (1981) Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41:144Google Scholar
  14. 14.
    Klubes P, Connelly K, Cerna I, Mandel HG (1978) Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5′-monophosphate and 2-deoxyuridine 5′-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors. Cancer Res 38:2325Google Scholar
  15. 15.
    Langenbach RJ, Danenberg PV, Heidelberger C (19712) Thymidylate synthetase: Mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 48:1565Google Scholar
  16. 16.
    Lee SS, Giovanella BC, Stehlin JS Jr, Brunn JC (1979) Regression of tumors established in nude mice after continuous infusion of thymidine. Cancer Res 39:2928Google Scholar
  17. 17.
    Lockshin A, Daneberg PV, Bloom ET (1980) Biochemical factors that decrease tightness of 5-fluoro-2′-deoxyuridylate (FdUMP) binding to purified human thymidylate synthetase (TSase). Proc Am Assoc Cancer Res 21:24Google Scholar
  18. 18.
    Myers CE, Young RC, Chabner BA (1975) Biochemical determinants of 5-fluorouracil response in vivo: The role of deoxyuridylate pool expansion. J Clin Invest 56:1231Google Scholar
  19. 19.
    Reyes P, Heibelberger C (1965) Fluorinated pyrimidines: Thymidylate synthetase: Its mechanism of action and inhibition by flourinated nucleotides. Mol Pharmacol 7:14Google Scholar
  20. 20.
    Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13:471Google Scholar
  21. 21.
    Ullman B, Melinda L, Martin DW, Santi DV (1978) Cytotoxicity of 5-fluoro-2′-deoxyuridine: Requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 75:980Google Scholar
  22. 22.
    Waxman S, Bruckner H, Wagle A, Schreiber C (1978) Potentiation of 5-fluorouracil (5-FU) antimetabolic effect by leucovorin (LV). Proc Am Assoc Cancer Res 19:149Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Philip Klubes
    • 1
  • Ingeborg Cerna
    • 1
  • Maura A. Meldon
    • 1
  1. 1.Department of PharmacologyThe George Washington University Medical CenterWashington, DCUSA

Personalised recommendations